- Home
- ROIV vs HSIC Comparison
ROIV vs HSIC Comparison
Compare ROIV & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | HSIC |
|---|---|---|
| Founded | 2014 | 1932 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 8.8B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | ROIV | HSIC |
|---|---|---|
| Price | $21.94 | $76.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | $21.94 | ★ $76.50 |
| AVG Volume (30 Days) | ★ 6.5M | 1.2M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.70 |
| EPS | N/A | ★ 3.17 |
| Revenue | $20,329,000.00 | ★ $12,938,000,000.00 |
| Revenue This Year | N/A | $5.35 |
| Revenue Next Year | $376.94 | $3.34 |
| P/E Ratio | ★ N/A | $24.16 |
| Revenue Growth | N/A | ★ 3.51 |
| 52 Week Low | $8.73 | $60.56 |
| 52 Week High | $22.45 | $82.49 |
Technical Indicators
Market Signals| Indicator | ROIV | HSIC |
|---|---|---|
| Relative Strength Index (RSI) | 68.21 | 66.60 |
| Support Level | $20.14 | $71.27 |
| Resistance Level | $21.48 | $77.46 |
| Average True Range (ATR) | 0.66 | 1.48 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 87.12 | 85.14 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.